- Home
- EXPI vs DNTH Comparison
EXPI vs DNTH Comparison
Compare EXPI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXPI | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EXPI | DNTH |
|---|---|---|
| Price | $9.03 | $41.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 980.2K | 645.0K |
| Earning Date | 02-19-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,678,653,000.00 | $3,078,000.00 |
| Revenue This Year | $6.03 | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $6.90 | $13.37 |
| 52 Week High | $12.23 | $45.46 |
Technical Indicators
Market Signals| Indicator | EXPI | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 25.25 | 49.47 |
| Support Level | $9.55 | $40.79 |
| Resistance Level | $9.94 | $43.40 |
| Average True Range (ATR) | 0.29 | 1.75 |
| MACD | -0.12 | -0.37 |
| Stochastic Oscillator | 4.80 | 36.15 |
Price Performance
Historical ComparisonAbout EXPI eXp World Holdings Inc.
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.